Since the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at
the end of 2019, thousands of SARS-CoV-2 mutations have been increasingly observed …

The COVID-19 pandemic has been a major reason behind the increased research aimed at
the identification of effective antiviral agents. Among these, Nucleoside analogs have shown …

Antiviral drug development for coronavirus disease 2019 (COVID-19) is occurring at an
unprecedented pace, yet there are still limited therapeutic options for treating this disease …

A class of pyrimidine thioglycoside analogs (6a–h) were synthesized from a reaction of 2-
cyano-3, 3-dimercapto-N-arylacrylamide (2a–d) and thiourea to produce the corresponding …

Given the rapid progression of the coronavirus disease 2019 (COVID‐19) pandemic, an
ultrafast response was urgently required to handle this major public crisis. To contain the …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the
global pandemic coronavirus disease 2019 (COVID-19), has proven itself to be a highly …

Nucleoside analogs (NAs) have been extensively examined as plausible antiviral agents in
recent years, in particular since the outbreak of the global pandemic of COVID-19 in 2019. In …

The ongoing COVID-19 pandemic has caused over six million deaths and huge economic
burdens worldwide. Antivirals against its causative agent, SARS-CoV-2, are in urgent …

ABSTRACT Molnupiravir (EIDD-2801/MK-4482), the prodrug of the active antiviral
ribonucleoside analog β-d-N4-hydroxycytidine (NHC; EIDD-1931), has activity against a …

There is an urgent need for an effective, oral, direct-acting therapeutic to block transmission
of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and prevent progression …